Drugs / anti-CHIKV hyperimmune immunoglobulins
anti-CHIKV hyperimmune immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02230163 | Sep 2014 → Oct 2015 | chikungunya | Centre Hospitalier Universitaire de la Guadeloupe | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CHIKV hyperimmune immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02230163 ↗ |
| Known as | Anti-CHIKV immunoglobulins | “Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections.” NCT02230163 ↗ |
| Known as | CHIKVIg | “Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections.” NCT02230163 ↗ |
| Modality | Protein / enzyme biologic | “Anti-CHIKV hyperimmune intravenous immunoglobulin” NCT02230163 ↗ |
| Route | Intravenous | “anti-CHIKV hyperimmune immunoglobulins given intravenously” NCT02230163 ↗ |